Where should I publish my paper?
Paste your title, abstract or keywords. The finder matches them to research topics and suggests ranked journals that publish most on those topics.
Journals for “HIV/AIDS drug development and treatment”
Suggested journals
Topic match is relative to the best match in this search (100% = best). Under each journal, "Publishes on" shows which of the matched topics it publishes and what share of its recent papers they make up. Fees are shown only where DOAJ records them.
| # | Journal | Topic match | ITS Journal Score | Global rank | Papers 2021–2025 | Open access | Fee (APC) | Compare |
|---|---|---|---|---|---|---|---|---|
| 1 | Antiviral Therapy SAGE Publishing · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (29%) | 100% | 65.3 | #9,628 | 118 | 94% | US$2,800 | |
| 2 | HIV Medicine Wiley · United Kingdom Publishes on: HIV/AIDS drug development and treatment (18%) | 62% | 71.8 | #5,787 | 938 | 61% | Not recorded | |
| 3 | AIDS Research and Therapy BioMed Central · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (18%) | 61% | 69.8 | #6,906 | 503 | 100% | 2,590 EUR | |
| 4 | Journal of AIDS and HIV Treatment Scientific Archives LLC Publishes on: HIV/AIDS drug development and treatment (22%) | 75% | 42.1 | #26,169 | 51 | 98% | Not recorded | |
| 5 | Journal of the International AIDS Society International AIDS Society · United States · DOAJ Publishes on: HIV/AIDS drug development and treatment (16%) | 55% | 77.7 | #3,005 | 1,017 | 100% | US$2,860 | |
| 6 | AIDS Research and Human Retroviruses Mary Ann Liebert, Inc. · United States Publishes on: HIV/AIDS drug development and treatment (17%) | 57% | 68.4 | #7,709 | 469 | 46% | Not recorded | |
| 7 | Current Opinion in HIV and AIDS Lippincott Williams & Wilkins · United Kingdom Publishes on: HIV/AIDS drug development and treatment (16%) | 53% | 73.6 | #4,803 | 311 | 50% | Not recorded | |
| 8 | Current HIV Research Bentham Science Publishers · The Netherlands Publishes on: HIV/AIDS drug development and treatment (17%) | 57% | 61.4 | #12,024 | 262 | 16% | Not recorded | |
| 9 | The Lancet HIV Elsevier BV · The Netherlands Publishes on: HIV/AIDS drug development and treatment (13%) | 43% | 81.2 | #1,774 | 887 | 45% | Not recorded | |
| 10 | Nucleosides Nucleotides & Nucleic Acids Taylor & Francis · United States Publishes on: HIV/AIDS drug development and treatment (14%) | 48% | 64.7 | #9,960 | 464 | 11% | Not recorded | |
| 11 | Journal of Antimicrobial Chemotherapy Oxford University Press · United Kingdom Publishes on: HIV/AIDS drug development and treatment (10%) | 33% | 83.4 | #1,142 | 2,343 | 60% | Not recorded | |
| 12 | HIV Research & Clinical Practice Taylor & Francis · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (14%) | 48% | 53.7 | #16,938 | 116 | 97% | US$2,990 | |
| 13 | AIDS Lippincott Williams & Wilkins · United Kingdom Publishes on: HIV/AIDS drug development and treatment (10%) | 35% | 76.8 | #3,377 | 1,669 | 61% | Not recorded | |
| 14 | HIV/AIDS - Research and Palliative Care Dove Medical Press · New Zealand · DOAJ Publishes on: HIV/AIDS drug development and treatment (12%) | 40% | 66.0 | #9,183 | 305 | 100% | US$3,565 | |
| 15 | Aids Reviews Spain Publishes on: HIV/AIDS drug development and treatment (14%) | 47% | 49.6 | #19,808 | 126 | 48% | Not recorded | |
| 16 | Medicinal Research Reviews Wiley · United States Publishes on: HIV/AIDS drug development and treatment (8%) | 28% | 85.1 | #816 | 397 | 46% | Not recorded | |
| 17 | Journal of Virus Eradication Elsevier BV · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (12%) | 42% | 57.3 | #14,606 | 537 | 100% | US$3,010 | |
| 18 | Current HIV/AIDS Reports Springer Science+Business Media · United States Publishes on: HIV/AIDS drug development and treatment (9%) | 30% | 75.4 | #3,922 | 230 | 75% | Not recorded | |
| 19 | Southern African Journal of HIV Medicine AOSIS · South Africa · DOAJ Publishes on: HIV/AIDS drug development and treatment (11%) | 38% | 61.3 | #12,131 | 206 | 100% | 13,637 ZAR | |
| 20 | JAIDS Journal of Acquired Immune Deficiency Syndromes Lippincott Williams & Wilkins · United States Publishes on: HIV/AIDS drug development and treatment (8%) | 29% | 77.0 | #3,269 | 1,209 | 76% | Not recorded | |
| 21 | AIDS Research and Treatment Hindawi Publishing Corporation · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (11%) | 36% | 53.6 | #16,999 | 68 | 100% | US$1,100 | |
| 22 | Enfermedades Infecciosas y Microbiología Clínica Elsevier BV · Spain Publishes on: HIV/AIDS drug development and treatment (7%) | 26% | 60.9 | #12,354 | 739 | 20% | Not recorded | |
| 23 | International Journal of STD & AIDS SAGE Publishing · United Kingdom Publishes on: HIV/AIDS drug development and treatment (4%) | 15% | 71.2 | #6,084 | 851 | 28% | Not recorded | |
| 24 | Retrovirology BioMed Central · United Kingdom · DOAJ Publishes on: HIV/AIDS drug development and treatment (4%) | 12% | 72.9 | #5,189 | 125 | 100% | 2,490 EUR | |
| 25 | AIDS Patient Care and STDs Mary Ann Liebert, Inc. · United States Publishes on: HIV/AIDS drug development and treatment (3%) | 11% | 73.9 | #4,665 | 331 | 61% | Not recorded | |
| 26 | JHA - Journal of HIV and Ageing Italy Publishes on: HIV/AIDS drug development and treatment (13%) | 44% | 10.5 | #60,127 | 90 | 100% | Not recorded | |
| 27 | Thai AIDS Journal Thailand Publishes on: HIV/AIDS drug development and treatment (13%) | 44% | 6.6 | #61,639 | 86 | 100% | Not recorded | |
| 28 | World Journal of AIDS Scientific Research Publishing · United States Publishes on: HIV/AIDS drug development and treatment (7%) | 24% | 39.2 | #29,268 | 57 | 100% | Not recorded | |
| 29 | Pharmacogenetics and Genomics Lippincott Williams & Wilkins · United Kingdom Publishes on: HIV/AIDS drug development and treatment (2%) | 7% | 66.2 | #9,110 | 163 | 33% | Not recorded |
Before you submit
Use this list as a shortlist, not a decision. For each journal, read its aims and scope and a few recent articles, check its peer-review and fee policy on its own website, and confirm any indexing (Scopus, Web of Science, PubMed) with the indexer itself. Be careful with journals that promise very fast acceptance or that contact you by email asking for papers.
How the ITS Journal Score works
One formula applies to every ranked journal, using open data from OpenAlex: 45% citation impact, 35% h-index and 20% size (papers published 2021–2025). Citation impact is the smaller of the journal's two-year mean citedness and its five-year citations per paper, so a journal whose output collapsed cannot jump to the top on old citations. Each part is half a percentile and half a log-scaled value, so the very top is still separated. Growth and open-access share are shown separately and are not part of the score.
A journal is ranked only if it published at least 50 papers in 2021–2025 and was active in at least five of the last six years. Field rankings compare a journal only with journals in the same field; the field is the OpenAlex field with most of the journal's recent papers, or "Multidisciplinary" when no field has 30% of them.
What this is not: the ITS Journal Score is not a Journal Impact Factor, CiteScore or SJR, and this site does not say whether a journal is indexed in Scopus, Web of Science or PubMed. Always confirm aims and scope, indexing, peer review and fees on the journal's own website before you submit.